Introduction
============

Rheumatic heart disease (RHD) is an autoimmune inflammatory disease with multiorgan involvement ([@b1-etm-0-0-4652]). RHD is caused by an abnormal immune response to group A streptococcal infection ([@b2-etm-0-0-4652]), which leads to valve damage, particularly to the mitral valve, and hemodynamic changes ([@b3-etm-0-0-4652]). In China, RHD remains a significant health burden, although the prevalence of RHD has been declining in recent years ([@b4-etm-0-0-4652]). Valve surgery is considered the primary clinical treatment for RHD ([@b5-etm-0-0-4652]). However, patients with RHD frequently suffer from serious complications and irreversible valve dysfunction due to a lack of early detection ([@b3-etm-0-0-4652]).

Pulmonary arterial hypertension (PAH) is the most frequent clinical complication of RHD ([@b6-etm-0-0-4652]). Right ventricular hypertrophy and heart failure during the later stages of PAH are attributable to significant reductions in the cross sectional area of pulmonary vasculature, which may eventually be fatal ([@b7-etm-0-0-4652],[@b8-etm-0-0-4652]). PAH is a complex disease; multiple factors contribute to its onset and development, including pathological environmental factors, genetic polymorphisms and epigenetic changes ([@b9-etm-0-0-4652]--[@b11-etm-0-0-4652]). Recent studies have demonstrated the role of epigenetic modifications in the pathogenesis of PAH ([@b11-etm-0-0-4652]--[@b13-etm-0-0-4652]), suggesting that DNA methylation may be associated with the etiology of RHD with secondary PAH (RHD-PAH).

DNA methylation typically occurs at the 5′ position of the cytosine ring in 5′-C-phosphate-G-3′ (CpG) dinucleotides and is often associated with the regulation of gene expression ([@b14-etm-0-0-4652]). DNA methylation serves an important role in the development and progression of rheumatic diseases ([@b15-etm-0-0-4652]--[@b17-etm-0-0-4652]). However, studies investigating the role of epigenetics in RHD-PAH are scarce. The present study aimed to identify differentially methylated regions (DMRs) in patients with RHD-PAH. The present study identified novel DNA methylation markers and will aid in improving the current understanding of RHD-PAH.

Materials and methods
=====================

### Sample collection, DNA extraction and bisulfite modification

The clinical diagnosis of RHD-PAH was performed as previously described ([@b3-etm-0-0-4652]). Specifically, the inclusion criteria were as follows: i) Diagnosis of mitral valve prolapse and scheduled for mitral valve replacement; ii) left ventricular ejection fraction volume \>50% and left ventricular end-diastolic diameter \<55 mm; iii) pulmonary artery systolic pressure \>40 mmHg prior to surgery; and iv) no history of cardiomyopathy, congenital heart disease, liver disease or renal disease. The present study was approved by the Ethics Committee of Lihuili Hospital and informed consent forms were signed by all participants. The clinical and pathological characteristics of the involved individuals are described in [Table I](#tI-etm-0-0-4652){ref-type="table"}. Since acute rheumatic fever occurs more frequently in females ([@b2-etm-0-0-4652]), a total of 6 female patients with RHD-PAH (the study group; age, 57.00±8.39 years) and 6 normal female donors (the control group; age, 55.00±6.39 years) were recruited for the present study from Lihuili Hospital (Ningbo, China) between March 2014 and September 2015.

Blood samples from the two groups of patients were collected into EDTA tubes. DNA extraction and quantification procedures were subsequently performed as previously described ([@b18-etm-0-0-4652]). Genomic DNA bisulfite conversion (500 ng) was performed using an EZ DNA Methylation-Gold^™^ kit (Zymo Research, Irvine, CA, USA), according to the manufacturer\'s protocol.

### Methylation assay

A methylation assay was performed using the Infinium HumanMethylation450 BeadChip kit (Illumina, Inc., San Diego, CA, USA) as described previously ([@b19-etm-0-0-4652]). In brief, bisulfite-converted DNA (200 ng) was used in the whole-genome amplification reaction, followed by an enzymatic end-point fragmentation, precipitation and resuspension in hybridization buffer ([@b19-etm-0-0-4652]). Subsequently, all steps were performed following the standard Infinium protocol. Sample labeling, hybridization to chips and image scanning were also carried out according to the Infinium kit\'s protocol ([@b20-etm-0-0-4652]). All samples were processed on a single chip to avoid the batch effect. A total of 485,577 methylation loci, covering 21,231 genes, were tested using this kit. Gene methylation datasets were submitted to the Gene Expression Omnibus (accession number GSE84003).

### Statistical analysis

Statistical analyses were conducted using R software version 3.0.1 ([www.r-project.org](www.r-project.org)). Methylation levels of CpG sites are expressed as β values ranging from 0--1. Methylation levels were measured using β-values, which are based on the fluorescence intensity of methylated and unmethy-lated probes. The calculation of β values was performed as previously described ([@b21-etm-0-0-4652]). Prior to further calculations, probes designed for sequences on sex chromosomes, with random single nucleotide polymorphisms in the probe-mapping genomic regions or with detection values of P\>0.01 on all arrays were removed. The remaining 463,289 probes were used for subsequent analysis. Methylation levels were then compared with the differential detection procedure in the Limma package version 3.30.13 ([www.bioconductor.org/packages/release/bioc/html/limma.html](www.bioconductor.org/packages/release/bioc/html/limma.html)) using R software, as previously described ([@b21-etm-0-0-4652]). P\<0.05 and an absolute value of ∆β\>0.2 were considered to indicate a statistically significant difference. The selection process is presented in [Fig. 1](#f1-etm-0-0-4652){ref-type="fig"}. IlluminaHumanMethylation450k.db annotation package version 2.0.9 (<http://www.bioconductor.org/packages/release/data/annotation/html/IlluminaHumanMethylation450k.db.html>) was used to provide detailed information about the 450k chip platform, including mappings between gene symbol identifiers and manufacturer identifiers and genomic positions. All annotations are based on human genome build 19. A heatmap was created via heatmap.2 function in the gplots package. Signaling pathway and gene ontology (GO) enrichment analyses were conducted using the Database for Annotation, Visualization and Integrated Discovery (DAVID; version 6.7; <http://david.abcc.ncifcrf.gov>) and the Kyoto Encyclopedia of Genes and Genomes (KEGG; [www.genome.jp/kegg](www.genome.jp/kegg)), respectively.

Results
=======

### Quality control of methylation data

Genome-wide DNA methylation profiles of the 12 samples were generated using the Infinium HumanMethylation450 BeadChip kit ([Fig. 1](#f1-etm-0-0-4652){ref-type="fig"}). The density distribution of the β-values is presented in [Fig. 2A](#f2-etm-0-0-4652){ref-type="fig"}. The results revealed a typical bimodal-shape distribution of β-values. Furthermore, boxplots of β-value distributions demonstrated homogenous levels of methylation across all of the samples ([Fig. 2B](#f2-etm-0-0-4652){ref-type="fig"}).

### DMRs between patients with RHD-PAH and healthy controls

The graph in [Fig. 3](#f3-etm-0-0-4652){ref-type="fig"} represents the distribution of CpG sites sorted by mean ∆β values and P-values ([Fig. 3](#f3-etm-0-0-4652){ref-type="fig"}). In the RHD-PAH group there were 40 hypomethylated and 64 hypermethylated CpG sites compared with the healthy controls. These 104 identified DMRs were mapped to 60 known genes (data not shown), such as protein kinase C alpha (PRKCA), fibroblast growth factor receptor 2, protamine 1, S-phase kinase associated protein 2 and hyperpolarization activated cyclic nucleotide gated potassium channel 2. A total of 17 (16.35%) of the DMRs were in promoter regions (5′UTR, TSS200, TSS1500 and 1stExon), 41 (39.42%) in gene body regions, 5 (4.81%) in 3′UTR regions and 41 (39.42%) were unknown.

The chromosomal distribution of DMRs was evaluated according to the annotation of genomic positions. It was revealed to affect a large range of genes and chromosomal regions ([Fig. 4](#f4-etm-0-0-4652){ref-type="fig"}). Patient samples were also ordered by hierarchical clustering, and a heat map was produced to allow the visualization of the hypermethylated DMRs associated with RHD-PAH ([Fig. 5](#f5-etm-0-0-4652){ref-type="fig"}). The DMRs were mapped to a number of genes, including PRKCA, protein kinase AMP-activated non-catalytic subunit γ 2 (PRKAG2), sprouty related EVH1 domain containing 2 (SPRED2) and LIF interleukin 6 family cytokine (LIF).

### Enrichment analysis of the genes with DMRs

DAVID GO enrichment analysis of the genes that the DMRs were mapped to revealed several significantly enriched GO terms, including negative regulation of protein kinase activity, positive regulation of protein amino acid phosphorylation, negative regulation of transferase activity and positive regulation of phosphate metabolic process (P\<0.05; [Table II](#tII-etm-0-0-4652){ref-type="table"}). PRKCA, PRKAG2, SPRED2 and LIF were each enriched in at least two of these processes. No significantly enriched signaling pathways were identified by KEGG.

Discussion
==========

In the present study, a genome-wide high-throughput assay was used to identify DMRs in Chinese patients with RHD-PAH. Rheumatic diseases, including RHD, frequently possess an element of autoimmunity ([@b22-etm-0-0-4652]). The hypomethylation of immune response-associated genes (cluster of differentiation 9, matrix metallopeptidase 9, platelet derived growth factor receptor α and bone marrow stromal cell antigen 2) has previously been identified in systemic lupus erythematosus ([@b23-etm-0-0-4652]), and DMRs in osteoarthritis are primarily associated with inflammatory/defensive immune responses ([@b24-etm-0-0-4652]). It has also been reported that the altered DNA methylation of genes, including interleukin (IL) 6 receptor, calpain 8, dipeptidyl peptidase 4 and multiple homeobox genes, may mediate the risk of rheumatoid arthritis ([@b25-etm-0-0-4652]).

In the present study, four candidate genes (PRKCA, LIF, PRKAG2 and SPRED2) were identified to be associated with the pathogenesis of RHD. Differentially methylated PRKCA contributes to the risk of developing fibromyalgia in women ([@b26-etm-0-0-4652]). Patients with fibromyalgia typically suffer from rheumatic symptoms, which are likely to be associated with inflammatory cytokines ([@b27-etm-0-0-4652]). LIF, which encodes a member of the IL-6 cytokine family, downregulates autoimmune responses by enhancing the number of regulatory T cells ([@b28-etm-0-0-4652]). This suggests that the silencing of LIF by hypermethylation may increase the risk of RHD. PRKAG2 mutation is responsible for glycogen storage disease of the heart ([@b29-etm-0-0-4652],[@b30-etm-0-0-4652]). However, the role of PRKAG2 in the development RHD-PAH remains unclear. SPRED2 has been reported to be a repressor of immune responses ([@b31-etm-0-0-4652]). The SPRED2 rs934734 polymorphism was identified to be significantly associated with an increased risk of rheumatoid arthritis ([@b32-etm-0-0-4652]), which suggests that SPRED2 may serve a role in the pathogenesis of RHD. However, further studies are required to explore the underlying mechanisms of these DMRs in the pathogenesis of RHD-PAH.

The present study had several limitations. The results of the current study were based on a genome-wide methylation array of 6 patients with RHD-PAH and 6 healthy controls, and large population validation for clinical application should be performed. Furthermore, the present study only included female Chinese patients with RHD-PAH, and so the DMRs identified here require confirmation in males and patients of different ethnicities. Finally, although DNA methylation regulation is an important mechanism in the pathogenesis of RHD-PAH, the involvement of other epigenetic regulation, including histone modification and the effects of miRNA, remains to be explored.

In conclusion, the results of the present study identified 40 hypomethylated and 64 hypermethylated CpG sites between the RHD-PAH group and the control group. These DMRs may provide novel insights into the pathogenesis of RHD-PAH.
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![Quality control of methylation data. (A) Density plots of the β-values for each Infinium assay type considered (blue: Infinium I; red: Infinium II). Infinium I assay: 2 bead types per CpG locus, both in the same color channel; Infinium II assay: 1 bead type per CpG locus, two color readout. (B) Boxplots of β-values in the 6 controls and 6 patients with rheumatic heart disease and secondary pulmonary arterial hypertension.](etm-14-02-1367-g01){#f2-etm-0-0-4652}

![Volcano plot of DMRs in the study group compared with the control group. Green lines represent the restricted conditions for discovering DMRs. Red dots indicate significant results (P\<0.05 and an absolute value of ∆β\>0.2). DMR, differentially methylated regions.](etm-14-02-1367-g02){#f3-etm-0-0-4652}

![Chromosomal distribution of significant DMRs between the study and control groups. Red lines represent DMRs. The length of the line represents the ∆β value. Upward lines are hypermethylated CpG sites and downward lines are hypomethylated CpG sites. DMR, differentially methylated regions.](etm-14-02-1367-g03){#f4-etm-0-0-4652}
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###### 

Clinical data for patients with rheumatic heart disease and secondary pulmonary arterial hypertension and healthy controls.

  Subgroup    Age (years)   Gender   PASP before surgery (mmHg)
  ----------- ------------- -------- ----------------------------
  Case 1      60            Female   42
  Case 2      56            Female   117
  Case 3      58            Female   72
  Case 4      56            Female   55
  Case 5      69            Female   50
  Case 6      43            Female   64
  Control 1   60            Female   NA
  Control 2   51            Female   NA
  Control 3   64            Female   NA
  Control 4   54            Female   NA
  Control 5   46            Female   NA
  Control 6   55            Female   NA

Patients in the study group had a high preoperative PASP (\>40 mmHg). PASP, pulmonary artery systolic pressure; NA, not applicable.

###### 

GO term enrichment analysis of the differentially methylated regions in patients with rheumatic heart disease and secondary pulmonary arterial hypertension compared with the healthy controls.

  Enriched term   Description                                                 P-value   Genes involved
  --------------- ----------------------------------------------------------- --------- -----------------------
  GO:0006469      Negative regulation of protein kinase activity              0.031     PRKCA, PRKAG2, SPRED2
  GO:0001934      Positive regulation of protein amino acid phosphorylation   0.032     PRKCA, LIF, PRKAG2
  GO:0051348      Negative regulation of transferase activity                 0.037     PRKCA, PRKAG2, SPRED2
  GO:0045937      Positive regulation of phosphate metabolic process          0.040     PRKCA, LIF, PRKAG2

GO, gene ontology; PRKCA, protein kinase C α; PRKAG2, protein kinase AMP-activated non-catalytic subunit γ 2; SPRED2, sprouty related EVH1 domain containing 2; LIF, LIF interleukin 6 family cytokine.
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